SENS Stock Overview A medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Senseonics Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Senseonics Holdings Historical stock prices Current Share Price US$0.46 52 Week High US$0.75 52 Week Low US$0.25 Beta 0.79 1 Month Change 45.51% 3 Month Change 32.16% 1 Year Change -23.96% 3 Year Change -84.41% 5 Year Change -49.25% Change since IPO -85.85%
Recent News & Updates
President recently bought US$98k worth of stock Dec 12
Senseonics Holdings, Inc. Re-Iterates Earnings Guidance for the Full Year 2024 Dec 10
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10 Senseonics Holdings, Inc. announced that it has received $16 million in funding
New major risk - Revenue and earnings growth Nov 08
New minor risk - Shareholder dilution Oct 28 See more updates
President recently bought US$98k worth of stock Dec 12
Senseonics Holdings, Inc. Re-Iterates Earnings Guidance for the Full Year 2024 Dec 10
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10 Senseonics Holdings, Inc. announced that it has received $16 million in funding
New major risk - Revenue and earnings growth Nov 08
New minor risk - Shareholder dilution Oct 28 Senseonics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $16 million. Oct 25
Senseonics Holdings, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Mercy Places First Commercial Eversense 365 Oct 11
New minor risk - Share price stability Sep 20
Consensus revenue estimates decrease by 12% Aug 15
Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint Aug 09
Senseonics Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Aug 09
Senseonics Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
Senseonics Holdings, Inc. Reaffirms Revenue Guidance for the First Half and Provides Revenue Guidance for the Full Year of 2024 Jun 24
First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat May 14
Senseonics Holdings, Inc. Announces Eversense CGM System Receives iCGM Designation by the U.S. Food and Drug Administration May 03
Senseonics Holdings, Inc. to Report Q1, 2024 Results on May 13, 2024 May 01
Senseonics Holdings, Inc., Annual General Meeting, May 22, 2024 Apr 13
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 03
Senseonics Holdings, Inc. Provides Revenue Guidance for the First Half of 2024 Mar 01
Consensus revenue estimates decrease by 22% Mar 01
Senseonics Holdings, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 16
Consensus EPS estimates fall by 12%, revenue upgraded Nov 16
Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023 Nov 11
Senseonics Holdings, Inc. Provides Earnings Guidance for the Year 2023 Nov 10
Senseonics Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 31
Senseonics Holdings, Inc. Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study Sep 27
Independent Non-Management Director recently bought US$162k worth of stock Sep 03
Price target decreased by 18% to US$1.67 Aug 15
New minor risk - Profitability Aug 12
Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint Aug 11
Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023 Aug 11
Senseonics Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
New major risk - Share price stability Jul 22
Investor sentiment improves as stock rises 29% Jul 18
Price target increased by 35% to US$2.75 Jul 01
Sensonics Holdings, Inc. Announces New Clinical Data Demonstrating the Safety and Accuracy of Eversense Through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions Jun 27
Senseonics Holdings, Inc. Elects Koichiro Sato as Directors May 25
Consensus estimates of losses per share improve by 33% May 16
Price target increased by 19% to US$2.50 May 10
Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2023 May 10
Full year 2022 earnings: EPS exceeds analyst expectations Mar 17
Consensus EPS estimates fall by 33% Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Senseonics Holdings, Inc. Revises Revenue Guidance for Full Year 2022 Nov 09
Senseonics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Senseonics Holdings, Inc. Announces CFO Transition Sep 02
Consensus forecasts updated Aug 16
Second quarter 2022 earnings: Revenues exceed analyst expectations Aug 10
Chief Operating Officer notifies of intention to sell stock Aug 08
Senseonics Holdings Inc. Announces Positive Coverage Decision for Eversense E3 CGM from Anthem Aug 04
Investor sentiment improved over the past week Aug 03
Senseonics Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Price target decreased to US$2.10 Jul 25
Investor sentiment improved over the past week Jul 08
Senseonics Holdings, Inc. Announces European Approval of the Next-Generation Eversense E3 Continuous Glucose Monitoring System Jun 16
Consensus revenue estimates increase by 23% May 17
Price target increased to US$4.25 May 16
Senseonics Holdings, Inc. Reiterates Revenue Guidance for the Full Year 2022 May 12
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 11
Senseonics Holdings, Inc., Annual General Meeting, May 26, 2022 Apr 16
Senseonics Holdings, Inc. Announces the First Patient Implant of the Eversense E3 CGM System in the U.S Apr 07
Independent Non-Management Director notifies of intention to sell stock Mar 18
Consensus revenue estimates fall by 13% Mar 08
Full year 2021 earnings: EPS misses analyst expectations Mar 04
Senseonics Holdings, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022 Mar 03
Price target increased to US$4.17 Mar 03
President recently sold US$1.1m worth of stock Feb 19 Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months
Senseonics Holdings, Inc. Provides Revenue Guidance for the Fiscal Year 2021 Jan 06
Chief Medical Officer & Director notifies of intention to sell stock Nov 20
Third quarter 2021 earnings released: EPS US$0.096 (vs US$0.099 loss in 3Q 2020) Nov 11
Independent Non-Management Director exercised options and sold US$410k worth of stock Aug 28
Independent Non-Management Director recently sold US$457k worth of stock Aug 28
Consensus forecasts updated Aug 17
Price target increased to US$2.58 Aug 11
Second quarter 2021 earnings released: US$0.42 loss per share (vs US$0.033 loss in 2Q 2020) Aug 11
Chief Medical Officer & Director notifies of intention to sell stock Jun 09
Senseonics Holdings, Inc Announces the Results of the Promise Study Evaluating the Accuracy and Safety of the Next Generation Eversense CGM System for Up to 180 Days with Reduced Calibrations Jun 04
Independent Non-Management Director Peter Klein has left the company Jun 04
Independent Non-Management Director notifies of intention to sell stock May 28
Consensus forecasts updated May 20
Senseonics Holdings, Inc. Reports Impairment Costs for the First Quarter Ended March 31, 2021 May 15
First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.21 loss in 1Q 2020) May 14
Senseonics Holdings, Inc. Provides Revenue Guidance for the Full Year 2021 May 14 Shareholder Returns SENS US Medical Equipment US Market 7D 2.9% -1.5% -2.4% 1Y -24.0% 10.0% 23.4%
See full shareholder returns
Return vs Market: SENS underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is SENS's price volatile compared to industry and market? SENS volatility SENS Average Weekly Movement 12.1% Medical Equipment Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SENS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SENS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company’s products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Show more Senseonics Holdings, Inc. Fundamentals Summary How do Senseonics Holdings's earnings and revenue compare to its market cap? SENS fundamental statistics Market cap US$273.73m Earnings (TTM ) -US$80.33m Revenue (TTM ) US$22.21m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SENS income statement (TTM ) Revenue US$22.21m Cost of Revenue US$24.53m Gross Profit -US$2.33m Other Expenses US$78.00m Earnings -US$80.33m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.13 Gross Margin -10.49% Net Profit Margin -361.77% Debt/Equity Ratio 262.9%
How did SENS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 02:10 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Senseonics Holdings, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gregory Chodaczek B. Riley Securities, Inc. Marie Thibault BTIG Sean Lavin BTIG
Show 9 more analysts 
